2020 Pediatric Rheumatology Symposium

April 29-May 2, 2020

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 155

Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) Is Characterized by a Novel Subset of Monocytes with Markers Associated with Crossing the Blood Brain Barrier (BBB)
Abstract Number: 012

Pediatric Antiphospholipid Syndrome: Clinical Features and Therapeutic Interventions in a Series of 22 Cases
Abstract Number: 051

Pediatric Providers’ Perspectives on Suspected Immune-Mediated Diffuse Alveolar Hemorrhage and Clinical Care Pathways
Abstract Number: 133

Pediatric Rheumatology Consultation for Both Traditional and Emerging Rheumatic Diseases in the Critical Care Setting
Abstract Number: 187

Perspectives of Adolescents and Young Adults Around Implementing Rheumatology Healthcare Transition: Preliminary Qualitative Findings
Abstract Number: 061

Perspectives of Radiologist Physicians in the Imaging of Chronic Nonbacterial Osteomyelitis
Abstract Number: 185

pGALS Training Increases Canadian and Kenyan Physicians’ Confidence in Examining the Musculoskeletal System in Children
Abstract Number: 124

Pharmacist Role in an Outpatient Adolescent Complex Pediatric Lupus Clinic
Abstract Number: 131

Practice Patterns for Consulting Pediatric Rheumatology in a Large Pediatric Intensive Care Unit
Abstract Number: 128

Predictors of Moderate/High Disease Activity in Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 136

Prevalence of Paradoxical Psoriasis After Exposure to Tumor Necrosis Factor Inhibitors (TNFi) in Children from a Single Tertiary Center
Abstract Number: 065

Prosthetic Temporomandibular Joint Replacement in a Cohort of Adolescent Patients with Juvenile Idiopathic Arthritis
Abstract Number: 091

Protracted Febrile Myalgia Findings on Magnetic Resonance Imaging
Abstract Number: 075

Pseudotumor Cerebri Syndrome in Children with Systemic Lupus Erythematosus
Abstract Number: 095

Pyoderma Gangrenosum Ulceration as a Presenting Feature of Pediatric Granulomatosis with Polyangiitis (GPA)

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].